← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Coastlands Capital LP
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0002068530
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 4
- Purchases · 24M
- 4
- Average purchase
- $39.8K
- Median purchase
- $42.8K
- Gross purchase value
- $159.3K
Companies: ADIAL PHARMACEUTICALS, INC. | Pasithea Therapeutics Corp.
4 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-16 | ADIAL PHARMACEUTICALS, INC. | ADIL | 10% Owner | $8.7K | Open filing |
| 2026-07-13 | ADIAL PHARMACEUTICALS, INC. | ADIL | 10% Owner | $32.6K | Open filing |
| 2026-07-01 | ADIAL PHARMACEUTICALS, INC. | ADIL | 10% Owner | $65.0K | Open filing |
| 2026-06-22 | Pasithea Therapeutics Corp. | KTTA | 10% Owner | $53.0K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small Sample | 75.0% (3/4) | 0.0% (0/3) | -2.3% | -2.0% | -2.6% |
| 20D | 3Small Sample | 75.0% (3/4) | 100.0% (3/3) | +45.6% | +39.0% | +17.6% |
| 60D | 1Small Sample | 25.0% (1/4) | 100.0% (1/1) | +46.5% | +46.5% | +46.5% |
| 120D | 0No Data | Awaiting maturity | — | — | — | — |
Research patterns
- First purchase in 12M
- 2/4
- Large purchase ≥ $100k
- 0/4
- Cluster buying · 15D
- 0/4
- Buying the dip
- 3/3
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.